Latest news with #RenalCellCarcinoma

Globe and Mail

Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment

DelveInsight's, 'Renal Cell Carcinoma Pipeline Insight 2025' report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape. Click here to read more @ Renal Cell Carcinoma Pipeline Outlook Key Takeaways from the Renal Cell Carcinoma Pipeline Report In May 2025, Merck Sharp & Dohme LLC announced a study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1. In May 2025, Karie Runcie announced a Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate. DelveInsight's Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment. The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others. Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others. Discover groundbreaking developments in Renal Cell Carcinoma therapies! Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Renal Cell Carcinoma Clinical Trials Assessment Renal Cell Carcinoma Emerging Drugs Profile CM082: Betta Pharmaceuticals CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma. IPI-549: Infinity Pharmaceuticals IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma. CMN-001: ColImmune Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma. The Renal Cell Carcinoma Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment. Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market. Stay informed about the Renal Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs Renal Cell Carcinoma Companies AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others. Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Subcutaneous Intravenous Intramuscular Molecule Type Renal Cell Carcinoma Products have been categorized under various Molecule types such as Bispecific Antibody Peptides Small molecule Gene therapy Product Type Transform your understanding of the Renal Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives Scope of the Renal Cell Carcinoma Pipeline Report Coverage- Global Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others. Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others. Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies Table of Content Introduction Renal Cell Carcinoma Executive Summary Renal Cell Carcinoma: Overview Renal Cell Carcinoma Pipeline Therapeutics Renal Cell Carcinoma Therapeutic Assessment Renal Cell Carcinoma – DelveInsight's Analytical Perspective In-depth Commercial Assessment Renal Cell Carcinoma Collaboration Deals Late Stage Products (Phase III) TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPI-549: Infinity Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) AVB-S6-500: Aravive Inc. Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company name Drug profiles in the detailed report….. Inactive Products Renal Cell Carcinoma Key Companies Renal Cell Carcinoma Key Products Renal Cell Carcinoma - Unmet Needs Renal Cell Carcinoma - Market Drivers and Barriers Renal Cell Carcinoma - Future Perspectives and Conclusion Renal Cell Carcinoma Analyst Views Renal Cell Carcinoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: